- Raised $8.4M funding round led by XT Venture Capital, Aug 2019
About
Sofwave Medical specializes in non-invasive aesthetic medical solutions to improve skin laxity, provide lifting effects, and enhance muscle toning.
Utilizing its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™), the Sofwave product delivers controlled ultrasound energy to the mid-dermal layer, stimulating collagen and elastin production and improving skin appearance with minimal downtime.
Clinically validated and supported by multiple broad FDA clearances, Sofwave's technologies offer effective solutions for patients seeking aesthetic enhancements without invasive procedures.
The introduction of the Pure Impact add-on module expands Sofwave's product portfolio, offering increased treatment versatility and efficiency to address a broader range of aesthetic concerns. Pure Impact is the world’s first plyometric muscle activation and toning device, emulating complex, compound full-body muscle movements.
Sofwave Plus Pure Impact is the ultimate complement to GLP-1 weight loss drugs. As these medications help with weight loss, Sofwave + Pure Impact ensures no muscle loss, increased tone, and decreased overall laxity, providing a comprehensive solution for enhancing physical appearance and health.
Backed by strong clinical data and regulatory endorsements, Sofwave Medical represents a significant opportunity for investors in a rapidly growing market segment.
Funding history · 1 round · $58.4M total
Q&A
- What is Sofwave Medical's primary focus?
- Sofwave Medical specializes in non-invasive aesthetic medical solutions designed to improve skin laxity, provide lifting effects, and enhance muscle toning.
- What is the core technology behind Sofwave Medical's products?
- Sofwave Medical utilizes its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™) to deliver controlled ultrasound energy to the mid-dermal layer, stimulating collagen and elastin production.
- When was Sofwave Medical founded?
- Sofwave Medical was founded in October 2015.
- What is the employee count for Sofwave Medical?
- Sofwave Medical has 51–200 employees.
- What is Sofwave Medical's current market capitalization?
- Sofwave Medical has a market capitalization of $303,534,131 USD.
- When did Sofwave Medical become a public company?
- Sofwave Medical became public on TASE in May 2021.
- What is the 'Pure Impact' add-on module offered by Sofwave Medical?
- The Pure Impact add-on module is described as the world’s first plyometric muscle activation and toning device, designed to emulate complex, compound full-body muscle movements.
- Who are the co-founders of Sofwave Medical?
- The co-founders of Sofwave Medical are Shimon Eckhouse, Ariel Sverdlik, and Genady Nahshon.
- What was Sofwave Medical's last funding round?
- Sofwave Medical's last funding round occurred in August 2019, with XT Venture Capital as a lead investor.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sofwave.com |
|---|---|
| linkedin.com/company/18755820 | |
| facebook.com/Sofwave/ | |
| YouTube | youtube.com/channel/UC3RyhVm1CRtmU0EscGI3FrA |
| instagram.com/sofwavemed/ | |
| Wikipedia | en.wikipedia.org/wiki/Sofwave_Medical |
| Wikidata | wikidata.org/wiki/Q110460022 |
Identifiers & details
| Former names | ArchimedUS Medical |
|---|---|
| Founded | 2015-10 |
| Employees (exact) | 188 |
| Offices | United States; Tustin |
| Market cap | $303.5M |
| Status reason | Public on TASE on May, 2021 |
| Wikidata QID | Q110460022 |
Radar intelligence
Patents
| EPO | 11 |
|---|
Web history (Wayback)
| Domain | sofwave.com |
|---|
Wikidata
| QID | Q110460022 |
|---|
Certificate / subdomain footprint
| Subdomains | 60 |
|---|